GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: ABL001 | CTX-009 | CTX009
Compound class:
Antibody
Comment: Tovecimig (CTX-009; formerly ABL001) is a bispecific monoclonal antibody that simultaneously blocks the signalling pathways that are activated by the delta-like ligand-4 (DLL4; Notch signaling) and vascular endothelial growth factor A (VEGF-A) [4]. The VEGF-A binding heavy chains of tovecimig are derived from the established anti-VEGF-A biologic bevacizumab. Two single chain variable fragments (scFv) that bind to human DLL4 are linked to the C-termini of the anti-VEGF-A heavy chains [1].
|
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 13128 | tovecimig |
Synonyms ![]() |
| ABL001 | CTX-009 | CTX009 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1654 |
| Other databases | |
| Search PubMed clinical trials | tovecimig |
| Search PubMed titles | tovecimig |
| Search PubMed titles/abstracts | tovecimig |